Fig. 2.
Survival after UDLI for CML according to disease state.
The solid line represents patients treated for early-phase relapse, and the dashed line represents patients treated for advanced-phase relapse. In this analysis, early-phase relapse includes patients classified as “accelerated phase” based solely on abnormal cytogenetic findings with no other clinical manifestations of advanced phase disease. This analysis shows improved survival for recipients of UDLI for early-phase relapse of CML.